Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021

Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine's effect on pneumonia incidence rate...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Emerging infectious diseases Ročník 30; číslo 3; s. 490 - 498
Hlavní autoři:	von Mollendorf, Claire, Ulziibayar, Munkhchuluun, Nguyen, Cattram D., Batsaikhan, Purevsuren, Suuri, Bujinlkham, Luvsantseren, Dashtseren, Narangerel, Dorj, de Campo, John, de Campo, Margaret, Tsolmon, Bilegtsaikhan, Demberelsuren, Sodbayar, Dunne, Eileen M., Satzke, Catherine, Mungun, Tuya, Mulholland, E. Kim
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States U.S. National Center for Infectious Diseases 01.03.2024 Centers for Disease Control and Prevention
Témata:	Age groups Air pollution bacteria children Conjugate vaccines Consent Disease Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021 hospitalization Hospitals Households Immunization Outdoor air quality Pandemics Patient outcomes PCV13 Pediatric research pneumococcal conjugate vaccine Pneumococcal vaccine Pneumonia Pneumonia in children Population Prevention Statistics Streptococcus infections Vaccines Mongolia Australia Asia Mongolia PCV13 bacteria hospitalization pneumonia children respiratory infections pneumococcal conjugate vaccine
ISSN:	1080-6040, 1080-6059, 1080-6059
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!